gdc
Breast CancerFDA NewsNewsworthy

Verzenio a New Targeted Therapy Approved for Metastatic Breast Cancer

Read about Verzenio, which was approved by the FDA in 2017, in combination with fulvestrant, for treatment of women with HR-positive, HER2-positive, HER2-negative advanced, or metastatic breast cancer that progressed after endocrine therapy.
December 2017 Vol 3 No 6

On September 28, 2017, the FDA approved Verzenio (abemaciclib; from Eli Lilly), a CDK4/CDK6 inhibitor, in combination with fulvestrant, for the treatment of women with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy, as well as for use alone in patients whose metastatic breast cancer progressed after endocrine therapy and after previous use of chemotherapy in the metastatic setting.

“Verzenio provides a new targeted treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class, it can be given as a stand-alone treatment to patients who were previously treated with endocrine therapy and chemotherapy,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approved Verzenio for these 2 uses based on clinical trials showing its benefits for patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The most common side effects with Verzenio are diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, and thrombocytopenia.

Recommended For You
Breast CancerCancer ScreeningWeb Exclusives
When Should I Get a Mammogram?
By John Parkinson
It’s important to understand the nuances of this test, along with your family history, so you can make an informed decision on when to begin testing and how frequently.
FDA NewsLeukemiaNewsworthy
Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
Last modified: March 25, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country